The French biotech company Ciloa creates its new GMP-compliant production unit as part of the development of a new generation of exosome-based vaccines and therapeutic vectors.
-
This first production unit is designed to meet GMP (Good Manufacturing Practices) standards, thereby ensuring the autonomy of Ciloa in the development of its biomanufacturing infrastructure and in the progress towards its future clinical studies.
-
The technology developed by Ciloa uses exosomes, small nanovesicles capable of transporting therapeutic proteins, for the development of a new generation of treatments and vaccines, notably in Covid-19 disease.
